Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2005

View Archived Issues

GAD: Spotlight on patients that "worry themselves sick"

Roche profiles successful quarter

Recordati licenses Stanate from InfaCare

Cardio Vascu-Grow shows preclinical potential for peripheral vascular disease

Enzo acquires rights to drug candidate for treating uveitis

Trimeris, ChemBridge Research Laboratories to develop HIV entry inhibitors

Orphan drug designation for Vical's CMV DNA vaccine

Novel antiinfective agents disclosed in recent patent literature

Profiling of recombinant human IGF-1 treatment

New therapeutics claimed for diabetes

Gallium maltolate demonstrates in vivo efficacy for RA

Mechanisms underlying new apoptosis-inducing agents developed by Maxim

Recent patents reveal new agents for hepatitis treatment

Cinacalcet reported effective in hyperparathyroidism after renal transplantation

Update on everolimus in the prevention of allograft rejection

Hematological changes reported for CC-4047 in multiple myeloma patients

Promising results found for inolimumab in steroid-resistant aGvHD

Scios convenes panel of cardiology experts to review Natrecor

Miraxion enters phase III trial for Huntington's disease

Exelixis submits IND for XL-184

Medarex and Boehringer Ingelheim enter antibody development agreement

Metabolic receives grant for phase I trial of ACV-1 for neuropathic pain

Expanded access program planned for protease inhibitor TMC-114

Indiplon capsules NDA accepted for review

Merck KGaA wins patent appeal

NDS filed for Abraxane in Canada

Mylan plans to outlicense nebivolol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...